Zacks Investment Research upgraded shares of Erytech Pharma (NASDAQ:ERYP) from a hold rating to a buy rating in a research note released on Friday morning. Zacks Investment Research currently has $10.00 target price on the stock.
According to Zacks, “Erytech Pharma S.A. operates as a biopharmaceutical company. It discovers and developes therapies for rare forms of cancer and orphan diseases. The company’s product pipeline consists of eryaspase, erymethionase, eryminase, ERYZYME and ERYMMUNE which are in clinical stages. It operates primarily in France and the United States. Erytech Pharma S.A. is based in France. “
Separately, ValuEngine downgraded Erytech Pharma from a buy rating to a hold rating in a research note on Wednesday, January 2nd.
A hedge fund recently bought a new stake in Erytech Pharma stock. Sphera Funds Management LTD. bought a new position in shares of Erytech Pharma SA (NASDAQ:ERYP) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 120,000 shares of the company’s stock, valued at approximately $1,046,000. Sphera Funds Management LTD. owned 0.67% of Erytech Pharma at the end of the most recent quarter. Institutional investors own 8.16% of the company’s stock.
About Erytech Pharma
ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
Featured Article: What is insider trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.